Innate Pharma (IPH) Q1 2026 TU earnings summary

Executive summary

• Advanced clinical pipeline with key assets progressing, including lacutamab, IPH4502, and monalizumab in collaboration with AstraZeneca.

• Confirmatory Phase 3 trial for lacutamab in CTCL planned for H2 2026, pending non-dilutive financing.

• Encouraging interim results from MATISSE Phase 2 trial for IPH5201 in NSCLC presented at AACR 2026.

• Streamlined organization with completed redundancy plan to align with strategic focus.

Financial highlights

• Cash, cash equivalents, and financial assets totaled €25.4 million as of March 31, 2026.

• Financial liabilities stood at €20.3 million at quarter-end.

• Revenue for Q1 2026 was €2.6 million, up from €1.2 million in Q1 2025, mainly from collaboration and licensing agreements.

• Cash runway anticipated until end of Q3 2026.

Outlook and guidance

• Initiation of lacutamab Phase 3 TELLOMAK-3 trial in H2 2026 contingent on securing non-dilutive financing.

• PACIFIC-9 Phase 3 trial with AstraZeneca targeting data readout in H2 2026.

• Continued enrollment in MATISSE Phase 2 for IPH5201 in PD-L1 ≥1% NSCLC patients.